Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) and endoscopic ultrasound-guided ethanol ablation (EUS-EA) of pancreatic neuroendocrine tumors and adenocarcinoma: a prospective multicenter study
EUS-RFA and EUS-EA can potentially treat lesions and control symptoms. EUS-RFA is a more promising and safer technique for managing functioning insulinomas. However, it cannot downstage pancreatic ductal adenocarcinoma patients. EUS-EA seems less efficient, with more adverse events than EUS-RFA.
Authors
- Mohammed Tag‐Adeen (ORCID: https://orcid.org/0000-0001-9813-3191)
- Elsayed Ghoneem (ORCID: https://orcid.org/0000-0003-2357-5299)
- Ahmed Youssef Altonbary (ORCID: https://orcid.org/0000-0001-8850-9829)
- Bogdan Miuţescu (ORCID: https://orcid.org/0000-0002-5336-5789)
- Hussein Okasha (ORCID: https://orcid.org/0000-0002-0815-1394)
- Eyad Gadour (ORCID: https://orcid.org/0000-0001-5087-1611)
- M Naguib (ORCID: https://orcid.org/0009-0001-9105-5175)
- Khaled Ragab (ORCID: https://orcid.org/0000-0001-8699-180X)
- Abeer Abdellatef
Institutions
- Cairo University (EG)
- Mansoura University (EG)
- South Valley University (EG)
- King Fahad Specialist Hospital (SA)
- Victor Babeș University of Medicine and Pharmacy Timișoara (RO)
- Research Institute of Ophthalmology (EG)
- Theodor Bilharz Research Institute (EG)
Publication Details
- Journal
- Gastroenterology Review
- Published
- 2025-01-01
- DOI
- https://doi.org/10.5114/pg.2025.151852
- Citations
- 1
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 1.35